BCG Vaccine Under Trial to Prevent Alzheimer's Disease in Israel
• A clinical trial in Israel is testing the century-old BCG vaccine, originally for tuberculosis, to assess its potential in slowing Alzheimer's disease.
• The trial is based on the theory that the BCG vaccine may stimulate immune cells in the brain, offering protection against Alzheimer's.
• Participants undergo cognitive and blood tests to evaluate biomarkers, with potential vaccine administration for those showing Alzheimer's risk indicators.
• Researchers aim to identify systemic factors driving Alzheimer's, contributing to the development of new drugs and preventive strategies.
NAYA Biosciences Initiates Phase 1/2a Trial of NY-303 for Hepatocellular Carcinoma
• NAYA Biosciences has commenced a Phase 1/2a clinical trial for NY-303, a GPC3-targeted NK Engager bispecific antibody, in patients with hepatocellular carcinoma (HCC).
• The trial will evaluate the safety and efficacy of NY-303 as a monotherapy in HCC patients who have not responded to first-line immunotherapy, starting in Israel.
• The Phase 1 portion will focus on dose escalation, while Phase 2a aims to assess objective response rate and progression-free survival, potentially expanding to the U.S. and Europe.
• NY-303's novel mechanism targets both NK cells and GPC3, offering a new approach for patients with limited treatment options and poor survival rates.
NAYA Biosciences Initiates Phase 1/2a Trial of NY-303 for Hepatocellular Carcinoma
• NAYA Biosciences has commenced a Phase 1/2a clinical trial for NY-303, a GPC3-targeting NK Engager bispecific antibody, in patients with hepatocellular carcinoma (HCC).
• The trial will assess the safety and efficacy of NY-303 as a monotherapy in patients who have not responded to first-line immunotherapy.
• Phase 1 will focus on dose escalation, while Phase 2a will expand to the US and Europe to evaluate objective response rate and progression-free survival.
• NY-303's novel mechanism targets both NK cells and GPC3, potentially overcoming resistance to checkpoint inhibitors in HCC.
NAYA Biosciences Initiates Phase 1/2a Trial of NY-303 for Hepatocellular Carcinoma
• NAYA Biosciences has commenced a Phase 1/2a clinical trial for NY-303, a GPC3-targeted NK Engager bispecific antibody, in patients with hepatocellular carcinoma (HCC).
• The trial will evaluate the safety and efficacy of NY-303 as a monotherapy in patients who have not responded to first-line immunotherapy.
• The Phase 1 portion will focus on dose escalation, while Phase 2a will assess objective response rate and progression-free survival in the US and Europe.
• NY-303's unique mechanism targets both NK cells and GPC3, potentially overcoming resistance to checkpoint inhibitors in HCC patients.
Nexcella's NXC-201 Shows Promise in Relapsed/Refractory Multiple Myeloma and AL Amyloidosis
• Nexcella's NXC-201, a BCMA-targeted CAR-T therapy, demonstrates promising clinical data in relapsed/refractory multiple myeloma and AL amyloidosis.
• Updated clinical data on NXC-201 will be presented at the 20th International Myeloma Society Annual Meeting in Athens, Greece.
• The NEXICART-1 trial, a Phase 1b/2a study, evaluates the safety and efficacy of NXC-201 in adults with relapsed/refractory multiple myeloma and AL amyloidosis.
• Nexcella plans to submit data to the FDA for NXC-201 in relapsed/refractory multiple myeloma and AL amyloidosis after treating a target number of patients.
Nexcella's NXC-201 CAR-T Therapy Shows 100% Response in Darzalex-Relapsed AL Amyloidosis
• Nexcella's NXC-201, a BCMA-targeted CAR-T cell therapy, demonstrated a 100% overall response rate in AL amyloidosis patients relapsed or refractory to Darzalex-based regimens.
• The Phase 1b/2a NEXICART-1 study showed a 63% complete response rate and a 75% organ response rate in treated patients with AL amyloidosis.
• The CAR-T therapy was well-tolerated, with no grade 4 cytokine release syndrome events reported, suggesting a favorable safety profile in this patient population.
• The best responder in the study had a duration of response of 16.5 months, with the response ongoing at the data cutoff, indicating sustained efficacy.
© Copyright 2025. All Rights Reserved by MedPath